Lower risk of HCC in chronic hepatitis B patients treated with tenofovir vs entecavir
Journal of Gastroenterology and Hepatology — Yuan BH, Li RH, Huo RR, et al. | January 27, 2022
i>NOTE, original article title: Lower risk of HCC with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: An updated meta‐analysis
In view of the controversial results from the previous smaller meta-analyses comparing the incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) vs entecavir (ETV), researchers conducted this updated meta-analysis with the aim to reliably identify if TDF and ETV treated CHB patients, in general or in specific subgroups, differ in terms of the HCC incidence.
From PubMed, EMBASE, Web of Science, and Cochrane Library, researchers identified 24 comparative studies involving 37,771 CHB patients treated with TDF and 72,094 treated with ETV for inclusion.
Evidence gained suggests an association of TDF with significantly reduced HCC risk compared with ETV treatment in patients who are from Asia and/or nucleos(t)ide naïve.